flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 Patients with type 2 #diabetes and chronic disease are at high risk for kidney failure, cardiovascular events, and death. ⁣ ⁣ Whether treatment with would mitigate these risks is unknown. ⁣ ⁣ Semaglutides Are Poised to Remake

Advertisement Article continues below this ad Empower, which says it has licenses to dispense drugs in all 50 states, has also faced scrutiny from the FDA over more than a decade of quality lapses, according to earlier reporting in the Chronicle

This delayed emptying creates a sensation of fullness that contributes to weight loss but can also trigger nausea, particularly after meals

Importantly, for many patients, heartburn and other gastrointestinal symptoms diminish over time as physiological adaptation occurs, though a subset of patients may experience persistent symptoms requiring intervention or medication discontinuation

Higher overall GI rate than semaglutid

some clients may also experience mild water retention or joint stiffness